CN1908666B - Enzyme linked immunity diagnose reagent kit for HB core antigen detecting in two sandwich method and application thereof - Google Patents
Enzyme linked immunity diagnose reagent kit for HB core antigen detecting in two sandwich method and application thereof Download PDFInfo
- Publication number
- CN1908666B CN1908666B CN200610019984A CN200610019984A CN1908666B CN 1908666 B CN1908666 B CN 1908666B CN 200610019984 A CN200610019984 A CN 200610019984A CN 200610019984 A CN200610019984 A CN 200610019984A CN 1908666 B CN1908666 B CN 1908666B
- Authority
- CN
- China
- Prior art keywords
- hepatitis
- enzyme
- core antigen
- sandwich method
- kit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 102000004190 Enzymes Human genes 0.000 title claims abstract description 33
- 108090000790 Enzymes Proteins 0.000 title claims abstract description 33
- 101710132601 Capsid protein Proteins 0.000 title claims abstract description 19
- 238000000034 method Methods 0.000 title claims description 45
- 239000003153 chemical reaction reagent Substances 0.000 title description 4
- 230000036039 immunity Effects 0.000 title 1
- 208000002672 hepatitis B Diseases 0.000 claims abstract description 40
- 238000003745 diagnosis Methods 0.000 claims abstract description 19
- 230000001900 immune effect Effects 0.000 claims abstract description 17
- 238000006243 chemical reaction Methods 0.000 claims abstract description 9
- 241000700721 Hepatitis B virus Species 0.000 claims description 15
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 11
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 11
- 238000010790 dilution Methods 0.000 claims description 10
- 239000012895 dilution Substances 0.000 claims description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 9
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims description 7
- 239000008363 phosphate buffer Substances 0.000 claims description 7
- 241000894006 Bacteria Species 0.000 claims description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 5
- 229940098773 bovine serum albumin Drugs 0.000 claims description 5
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 claims description 5
- 229940033663 thimerosal Drugs 0.000 claims description 5
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 4
- 238000004587 chromatography analysis Methods 0.000 claims description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 4
- 238000005215 recombination Methods 0.000 claims description 4
- 230000006798 recombination Effects 0.000 claims description 4
- QLLOPPVDGOTIMW-UHFFFAOYSA-N N1=CN=C2N=CNC2=C1.NC=1NC=CC1 Chemical compound N1=CN=C2N=CNC2=C1.NC=1NC=CC1 QLLOPPVDGOTIMW-UHFFFAOYSA-N 0.000 claims description 3
- 238000012870 ammonium sulfate precipitation Methods 0.000 claims description 3
- 239000003480 eluent Substances 0.000 claims description 2
- 238000000746 purification Methods 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 238000001514 detection method Methods 0.000 abstract description 30
- 230000035945 sensitivity Effects 0.000 abstract description 9
- 239000003795 chemical substances by application Substances 0.000 abstract description 2
- 150000001875 compounds Chemical class 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 description 27
- 210000002966 serum Anatomy 0.000 description 22
- 239000000427 antigen Substances 0.000 description 15
- 238000002965 ELISA Methods 0.000 description 10
- 102000036639 antigens Human genes 0.000 description 10
- 108091007433 antigens Proteins 0.000 description 10
- 238000009007 Diagnostic Kit Methods 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 5
- 239000000872 buffer Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 3
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical class OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 3
- 238000003118 sandwich ELISA Methods 0.000 description 3
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010029719 Nonspecific reaction Diseases 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000011895 specific detection Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 101000619542 Homo sapiens E3 ubiquitin-protein ligase parkin Proteins 0.000 description 1
- 102100034349 Integrase Human genes 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- SPSXSWRZQFPVTJ-ZQQKUFEYSA-N hepatitis b vaccine Chemical compound C([C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)OC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)C1=CC=CC=C1 SPSXSWRZQFPVTJ-ZQQKUFEYSA-N 0.000 description 1
- 229940124736 hepatitis-B vaccine Drugs 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 102000045222 parkin Human genes 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Images
Landscapes
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200610019984A CN1908666B (en) | 2006-08-14 | 2006-08-14 | Enzyme linked immunity diagnose reagent kit for HB core antigen detecting in two sandwich method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200610019984A CN1908666B (en) | 2006-08-14 | 2006-08-14 | Enzyme linked immunity diagnose reagent kit for HB core antigen detecting in two sandwich method and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1908666A CN1908666A (en) | 2007-02-07 |
CN1908666B true CN1908666B (en) | 2010-05-12 |
Family
ID=37699838
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200610019984A Expired - Fee Related CN1908666B (en) | 2006-08-14 | 2006-08-14 | Enzyme linked immunity diagnose reagent kit for HB core antigen detecting in two sandwich method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1908666B (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102043050A (en) * | 2009-10-23 | 2011-05-04 | 上海荣盛生物药业有限公司 | In vitro detection method of hepatitis B virus C antibody |
CN102062779A (en) * | 2009-11-17 | 2011-05-18 | 上海荣盛生物药业有限公司 | Composition for in-vitro detection of hepatitis B virus C antibody |
CN103217533B (en) * | 2012-01-21 | 2016-01-06 | 厦门大学 | Anti-HBc quantitative detecting method and the purposes in monitoring Chronic Hepatitis B PD and predicted treatment curative effect thereof |
CN103616511A (en) * | 2013-12-06 | 2014-03-05 | 苏州长光华医生物医学工程有限公司 | Hepatitis B core antibody measurement kit and detection method thereof |
CN106785256B (en) * | 2017-01-18 | 2021-01-15 | 苏州富电通讯有限公司 | Medium comb filter |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1132857A (en) * | 1995-10-31 | 1996-10-09 | 刘毅维 | Detection method of core antigen of hepatitis virus |
EP1354204A2 (en) * | 2000-06-15 | 2003-10-22 | Chiron Corporation | Hcv antigen/antibody combination assay |
-
2006
- 2006-08-14 CN CN200610019984A patent/CN1908666B/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1132857A (en) * | 1995-10-31 | 1996-10-09 | 刘毅维 | Detection method of core antigen of hepatitis virus |
EP1354204A2 (en) * | 2000-06-15 | 2003-10-22 | Chiron Corporation | Hcv antigen/antibody combination assay |
Non-Patent Citations (2)
Title |
---|
刘琦 等.两种抗体纯化方法对乙肝核心抗体酶标试剂盒质量的影响.华中科技大学学报31 1.2002,31(1),108-110. |
刘琦 等.两种抗体纯化方法对乙肝核心抗体酶标试剂盒质量的影响.华中科技大学学报31 1.2002,31(1),108-110. * |
Also Published As
Publication number | Publication date |
---|---|
CN1908666A (en) | 2007-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Jongerius et al. | New hepatitis B virus mutant form in a blood donor that is undetectable in several hepatitis B surface antigen screening assays | |
Chau et al. | Serodiagnosis of recent hepatitis B infection by IgM class anti–HBc | |
Deguchi et al. | Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay | |
Lin et al. | Diagnostic value of immunoglobulin G (IgG) and IgM anti-hepatitis E virus (HEV) tests based on HEV RNA in an area where hepatitis E is not endemic | |
Sjogren et al. | Immunoglobulin M antibody to hepatitis B core antigen in patients with chronic type B hepatitis | |
Roggendorf et al. | Immunoglobulin M antibodies to hepatitis B core antigen: evaluation of enzyme immunoassay for diagnosis of hepatitis B virus infection | |
Li et al. | Novel double-antigen sandwich immunoassay for human hepatitis B core antibody | |
Mushahwar et al. | Prevalence of hepatitis B e antigen and its antibody as detected by radioimmunoassays | |
CN1908666B (en) | Enzyme linked immunity diagnose reagent kit for HB core antigen detecting in two sandwich method and application thereof | |
CA1148859A (en) | Simultaneous assay of two hepatitis viruses using a solid phase | |
CN108344869B (en) | Hepatitis B surface antigen chemiluminescence immunoassay kit and application thereof | |
Weber et al. | Evaluation of two new automated assays for hepatitis B virus surface antigen (HBsAg) detection: IMMULITE HBsAg and IMMULITE 2000 HBsAg | |
CN101975859A (en) | Magnetic microparticle separation chemiluminescent immunoassay detection method for hepatitis B virus surface antigen | |
Takahashi et al. | Determination of e antigen and antibody to e by means of passive hemagglutination method | |
US6150113A (en) | Method for increasing specificity in competitive immunoassays | |
Swenson et al. | Determination of HBsAg subtypes in different high risk populations using monoclonal antibodies | |
Guillou et al. | Evaluation of an enzyme‐linked immunosorbent assay for detection and quantification of hepatitis B virus PreS1 envelope antigen in serum samples: comparison with two commercial assays for monitoring hepatitis B virus DNA | |
Clement et al. | Evaluation of a new rapid test for the combined detection of hepatitis B virus surface antigen and hepatitis B virus e antigen | |
Eble et al. | Differential diagnosis of acute viral hepatitis using rapid, fully automated immunoassays | |
Kryger et al. | Enzyme-linked immunosorbent assay for detection of immunoglobulin M antibody to hepatitis B core antigen | |
JP2524101B2 (en) | Immunodetermination method for detection of common determinant antibody against hepatitis B | |
CN102798718A (en) | Previous S1 antigen detection kit for hepatitis B virus and preparation method of previous S1 antigen detection kit | |
Weare et al. | Improvement in the specificity of assays for detection of antibody to hepatitis B core antigen | |
Ni et al. | Absence or delayed appearance of hepatitis B core antibody in chronic hepatitis B surface antigen carrier children | |
Pujol et al. | A double sandwich monoclonal enzyme immunoassay for detection of hepatitis B surface antigen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: CHANGSHU ZIJIN INTELLECTUAL PROPERTY SERVICE CO., Free format text: FORMER OWNER: WUHAN UNIVERSITY Effective date: 20121218 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 430072 WUHAN, HUBEI PROVINCE TO: 215500 SUZHOU, JIANGSU PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20121218 Address after: 215500 Changshou City South East Economic Development Zone, Jiangsu, Jin Road, No. 8 Patentee after: Changshu Zijin Intellectual Property Service Co., Ltd. Address before: 430072 Hubei city of Wuhan province Wuchang Luojiashan Patentee before: Wuhan University |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160524 Address after: 110117 Liaoning city of Shenyang Province Hunnan International Software Park Museum B01 401 Patentee after: Weiwoke information Polytron Technologies Inc Address before: 215500 Changshou City South East Economic Development Zone, Jiangsu, Jin Road, No. 8 Patentee before: Changshu Zijin Intellectual Property Service Co., Ltd. |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160613 Address after: 110000 No. 33-1, Hai Lu, Shenyang economic and Technological Development Zone, Liaoning Patentee after: SHENYANG HUIMIN BIOTECHNOLOGY CO., LTD. Address before: 110117 Liaoning city of Shenyang Province Hunnan International Software Park Museum B01 401 Patentee before: Weiwoke information Polytron Technologies Inc |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100512 Termination date: 20180814 |